Loading
Wave Life Sciences Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by RA CAPITAL MANAGEMENT, L.P., was filed 30 Mar 2026.
Wave Life Sciences Ltd.: what insiders have been doing
Every trade that managers of Wave Life Sciences Ltd. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Boston, United States. Over the twelve months to 19 October 2026, 34 filings were filed, from 15 insiders.
The record shows 3 purchases on the open market worth €49.8M, made by 2 insiders, against 9 sales worth €607k by 7 insiders. Purchases outweigh sales by €49.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 senior executive. At €26.0M, the purchase published on 30 March 2026 by RA Capital Management, L.P. is the largest of the period.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 30 March 2026, 203 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 34 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2022, counts 7 purchases against 30 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 42.7 m USD and net income of -204.4 m USD.
For comparison within the same sector, see the insider buying recorded at Vivos Inc and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
94
Thresholds
n/a
Buy Volume
€109M
7 ops. · all time
Sell Volume
€7M
30 ops. · all time
Who traded when
BuySaleAik Na Tan3 sales
Gregory L. Verdine3 sales
Adrian Rawcliffe2 sales
Ken Takanashi2 sales
Paul Bolno2 sales
RA Capital Management, L.P.2 buys
+4 other insiders
Since the insiders bought
- -56.5%Entry US$7.25 · Close 16 Oct 2026 US$3.15
- -24.4%Entry US$16.41 · Close at T+90 US$12.41
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Wave Life Sciences Ltd. Strong Buy (bullish), based on 20 analysts. Average price target: US$17.22.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.13
Analyst consensus
20 analystsStrong buy
US$8.37Target US$17.22(+450%)US$42.00
Income statement
RevenueUS$42.7M
EBITDA-US$206.5M-483% margin
Net income-US$204.4M-478.3% margin
Valuation
PER (forward)-2.7x
P/Book1.3x
Beta-1.43
Balance sheet & cash
Market capUS$616.8M
Total debtUS$17.8M
Free Cash Flow-US$188.2M
Debt / Equity10%
Profitability & ownership
ROE-67.4%
ROA-33.6%
% insiders15.6%
% institutions85.7%
Last declaration on 7 October 2026
Declarations94 total
10,700 shares0Common StockSEC:0001231919-26-001433:0
10,700 shares0Common StockSEC:0001193125-26-417232:0
10,700 shares0Common StockSEC:0001193125-26-417237:0
10,700 shares0Common StockSEC:0001193125-26-417236:0
10,700 shares0Common StockSEC:0001193125-26-417235:0
10,700 shares0Common StockSEC:0001193125-26-417234:0
10,700 shares0Common StockSEC:0001193125-26-417233:0
10,700 shares0Common StockSEC:0001193125-26-417231:0
12,700 shares@ US$5.290.0085% mcap100.0% of flowCommon StockSEC:0001193125-26-349962:0
3,864 shares@ US$6.010.0029% mcap100.0% of flowCommon StockSEC:0001193125-26-349961:0
7,000 shares@ US$5.970.0053% mcap49.8% of flowCommon StockSEC:0001193125-26-349963:0
7,000 shares@ US$6.010.0053% mcap50.2% of flowCommon StockSEC:0001193125-26-349963:1
432 shares@ US$6.010.0003% mcap100.0% of flowCommon StockSEC:0001193125-26-349960:0
12,700 shares@ US$5.0450.0085% mcap100.0% of flowCommonSEC144:0001950047-26-008025
7,000 shares@ US$6.070.0054% mcap100.0% of flowCommonSEC144:0001950047-26-007963
4,954,558 shares@ US$6.0652.0% of flowOrdinary SharesSEC:0001231919-26-000297:0
Canonical exit: 24 Jun 2026 (T+90)
3,901,348 shares0Ordinary SharesSEC:0001193125-26-126276:0
17,900 shares@ US$3.873.9% of flowOrdinary SharesSEC:0001193125-26-083712:0
45,625 shares0Ordinary SharesSEC:0001193125-26-047323:0
165,000 shares0Ordinary SharesSEC:0001193125-26-047322:0
38,750 shares0Ordinary SharesSEC:0001193125-26-047319:0
45,625 shares0Ordinary SharesSEC:0001193125-26-047314:0
9,375 shares@ US$3.141.6% of flowOrdinary SharesSEC:0001193125-26-005195:0
42,000 shares@ US$5.9769.5% of flowOrdinary SharesSEC:0001193125-25-314742:0
25 of 94 declarations
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a Nasdaq-listed biotechnology company in the United States focused on RNA medicines, an emerging and potentially differentiated area of drug development. The company was incorporated in 2012 and its U.S. headquarters are in Cambridge, Massachusetts, placing it in one of the world’s leading life-sciences clusters. Wave is best described as a clinical-stage biotech: it is not a mature commercial pharma group, but a company trying to convert proprietary platform science into high-value therapies for genetically defined diseases.
Its business model is built around a proprietary oligonucleotide chemistry and design platform, originally associated with PRISM, and now extended into RNA editing and siRNA approaches. In practical terms, Wave is targeting indications where strong genetic validation can support clearer clinical hypotheses and, if successful, premium product economics. The company’s lead and most closely watched programs are WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency (AATD), and WVE-008 for PNPLA3-related liver disease. Wave also retains clinical and research programs in Duchenne muscular dystrophy and Huntington’s disease, giving it a broader scientific footprint while staying focused on specialized, high-unmet-need areas.
Read moreShow less
From a competitive standpoint, Wave operates in a very crowded innovation landscape, competing with other RNA-therapeutics developers as well as disease-focused biotech peers. Its investment case is driven by platform differentiation, target validation, and the potential for durable or infrequent dosing regimens, which are particularly attractive in chronic diseases. The company also maintains an international operating structure, with research and development activities in the United States and Japan, reinforcing its position as a globally organized biotechnology platform rather than a purely domestic U.S. company.
Recent milestones have been important. In 2025 and 2026, Wave reported encouraging clinical updates for WVE-007 and WVE-006, highlighted its plan to accelerate the RNA-editing portfolio, and entered 2026 with strengthened liquidity following a sizable capital raise. The company also announced in 2026 that it regained full rights to WVE-006 from GSK, which may improve strategic flexibility and long-term value creation. For investors, Wave remains a classic high-risk/high-upside biotech story: technologically ambitious, scientifically interesting, and still dependent on successful clinical execution, regulatory progress, and continued access to capital.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
